Hanninen, Mikael, Peter Venner, and Scott North. “A Rapid PSA Half-Life Following Docetaxel Chemotherapy Is Associated With Improved Survival in Hormone Refractory Prostate Cancer”. Canadian Urological Association Journal 3, no. 5 (May 1, 2013): 369–74. Accessed May 10, 2024. https://cuaj.ca/index.php/journal/article/view/1145.